About this medicine
Product information is provided to support understanding and conversations with your care team. Follow the approved leaflet and your prescriber’s instructions.
Content migrated from the company website; pending clinical review before final publication.
Dosage forms
Oral tablets (40 mg)
Drug class
Tyrosine kinase inhibitor; multikinase tyrosine kinase inhibitor (VEGFR, PDGFR, FGFR)
Administration
Preferably take at a consistent time each day after a low-fat meal (less than 600 calories and 30% fat). Usually taken as 160 mg daily in four-week treatment cycles (three weeks of treatment followed by one week off).
Uses
• Metastatic colorectal cancer
• Gastrointestinal stromal tumor (GIST): advanced or unresectable
• Hepatocellular carcinoma (HCC)
Competitive advantages
Regorafenib is a potent multikinase tyrosine kinase inhibitor, with a particular role in inhibiting vascular endothelial growth factor (VEGF) and pathways related to cell growth and proliferation. It is used as a second-line treatment in treatment-resistant cancers, including metastatic colorectal cancer, gastrointestinal stromal tumors and hepatocellular cancer. Its high effectiveness and ability to control disease progression in patients resistant to other treatments make it a suitable choice for specialists.
Original company product page ↗